Bellicum Pharmaceuticals Announces Patent on CaspaCIDe Method for Selectively Eliminating Therapeutic Cells
“These additional patent claims broaden and strengthen the intellectual
property around our clinically validated CaspaCIDe cell therapy safety
system,” commented
The patent relates to the on-demand in vivo elimination of
therapeutic cells, (such as CAR T, TCR and stem cells) that have been
modified to express the iCasp9 protein. When the small molecule
rimiducid is administered to a patient, the induced dimerization of
iCasp9 results in the rapid death of these modified cells. Bellicum has
worldwide exclusive rights to the clinical use of rimiducid and other
dimerizers from
About
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
About
Forward-Looking Statement
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Bellicum may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue," “designed,”
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: our
research and development activities relating to CAR Ts, TCRs and to
CaspaCIDe; the effectiveness of BPX-501, its possible range of
application and potential curative effects and safety in the treatment
of diseases, and risks related to our reliance on our license
agreements with ARIAD and BCM. Various factors may cause differences
between Bellicum’s expectations and actual results as discussed in
greater detail under the heading “Risk Factors” in Bellicum’s filings
with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160720005386/en/
Source:
Bellicum Pharmaceuticals
Investors:
Alan Musso,
CFO, 832-384-1116
amusso@bellicum.com
or
Media:
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com